Patents by Inventor Wenwei Huang
Wenwei Huang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10940188Abstract: The present invention concerns the use of compounds for the treatment or prevention of Flavivirus infections, such as Zika virus infections. Aspects of the invention include methods for treating or preventing Flavivirus virus infection, such as Zika virus infection, by administering a compound or class of compound disclosed herein, such as a niclosamide compound, an emricasan compound, a cyclin-dependent kinase inhibitor, a proteasome inhibitor, or a combination of two or more of the foregoing, to a subject in need thereof; methods for inhibiting Flavivirus infections such as Zika virus infections in a cell in vitro or in vivo; pharmaceutical compositions; packaged dosage formulations; and kits for treating or preventing Flavivirus infections, such Zika virus infections.Type: GrantFiled: January 31, 2020Date of Patent: March 9, 2021Assignees: FLORIDA STATE UNIVERSITY RESEARCH FOUNDATION, INC., THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, THE JOHNS HOPKINS UNIVERSITYInventors: Hengli Tang, Emily M. Lee, Yichen Cheng, Yi Zhou, Wei Zheng, Ruili Huang, Miao Xu, Wenwei Huang, Menghang Xia, Hongjun Song, Guo-Li Ming, Zhexing Wen
-
Publication number: 20200289471Abstract: The present invention concerns the use of compounds and compositions for the treatment or prevention of Flavivirus infections, such as dengue virus infections and Zika virus infections. Aspects of the invention include methods for treating or preventing Flavivirus virus infection, such as dengue virus and Zika virus infection, by administering a compound or composition of the invention, to a subject in need thereof; methods for inhibiting Flavivirus infections, such as dengue virus and Zika virus infections, in a cell in vitro or in vivo; pharmaceutical compositions; packaged dosage formulations; and kits useful for treating or preventing Flavivirus infections, such as dengue virus and Zika virus infections.Type: ApplicationFiled: April 29, 2020Publication date: September 17, 2020Inventors: HENGLI TANG, EMILY M. LEE, WEI ZHENG, RUILI HUANG, MIAO XU, WENWEI HUANG, KHALIDA SHAMIM, GUOLI MING, HONGJUN SONG
-
Publication number: 20200197369Abstract: The present invention concerns the use of compounds and compositions for the treatment or prevention of Flavivirus infections, such as dengue virus infections and Zika virus infections. Aspects of the invention include methods for treating or preventing Flavivirus virus infection, such as dengue virus and Zika virus infection, by administering a compound or composition of the invention, to a subject in need thereof; methods for inhibiting Flavivirus infections, such as dengue virus and Zika virus infections, in a cell in vitro or in vivo; pharmaceutical compositions; packaged dosage formulations; and kits useful for treating or preventing Flavivirus infections, such as dengue virus and Zika virus infections.Type: ApplicationFiled: December 19, 2019Publication date: June 25, 2020Inventors: HENGLI TANG, EMILY M. LEE, WEI ZHENG, RUILI HUANG, MIAO XU, WENWEI HUANG, KHALIDA SHAMIM, GUOLI MING, HONGJUN SONG
-
Publication number: 20200179389Abstract: The present invention provides small-molecule inhibitors of BMP signaling and compositions and methods for inhibiting BMP signaling. These compounds and compositions may be used to modulate cell growth, differentiation, proliferation, and apoptosis, and thus may be useful for treating diseases or conditions associated with BMP signaling, including inflammation, cardiovascular disease, hematological disease, cancer, and bone disorders, as well as for modulating cellular differentiation and/or proliferation. These compounds and compositions may also be used to treat subjects with Sjögren's syndrome, or diffuse intrinsic pontine glioma (DIPG).Type: ApplicationFiled: April 26, 2018Publication date: June 11, 2020Inventors: Paul B. Yu, Wenwei Huang, Philip Edward Sanderson, Jian-Kang Jiang, Khalida Shamim, Wei Zheng, Xiuli Huang, Gregory Tawa, Arthur Lee, Asaf Alimardanov, Junfeng Huang
-
Publication number: 20200164051Abstract: The present invention concerns the use of compounds for the treatment or prevention of Flavivirus infections, such as Zika virus infections. Aspects of the invention include methods for treating or preventing Flavivirus virus infection, such as Zika virus infection, by administering a compound or class of compound disclosed herein, such as a niclosamide compound, an emricasan compound, a cyclin-dependent kinase inhibitor, a proteasome inhibitor, or a combination of two or more of the foregoing, to a subject in need thereof; methods for inhibiting Flavivirus infections such as Zika virus infections in a cell in vitro or in vivo; pharmaceutical compositions; packaged dosage formulations; and kits for treating or preventing Flavivirus infections, such Zika virus infections.Type: ApplicationFiled: January 31, 2020Publication date: May 28, 2020Inventors: HENGLI TANG, EMILY M. LEE, YICHEN CHENG, YI ZHOU, WEI ZHENG, RUILI HUANG, MIAO XU, WENWEI HUANG, MENGHANG XIA, HONGJUN SONG, GUO-LI MING, ZHEXING WEN
-
Publication number: 20200121672Abstract: The present invention concerns the use of emetine compounds for the treatment or prevention of Flavivirus infections, such as dengue virus infections. Aspects of the invention include methods for treating or preventing Flavivirus virus infection, such as dengue virus infection, by administering an emetine compound such as emetine or cephaeline, or a combination of two or more emetine compounds, to a subject in need thereof; methods for inhibiting Flavivirus infections such as dengue virus infections in a cell in vitro or in vivo; pharmaceutical compositions; packaged dosage formulations; and kits for treating or preventing Flavivirus infections, such dengue virus infections.Type: ApplicationFiled: December 18, 2019Publication date: April 23, 2020Inventors: HENGLI TANG, EMILY M. LEE, ANIL MATHEW THARAPPEL, HONGJUN SONG, GUO-LI MING, WEI ZHENG, MIAO XU, SHU YANG, RUILI HUANG, WENWEI HUANG, KHALIDA SHAMIM, HAO LI
-
Patent number: 10561666Abstract: Amido compounds are disclosed that have a formula represented by the following: and wherein n1, n2, R1a, R1b, R2, R3, R4, R5, and R6 are as described herein. The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, inflammatory conditions, autoimmune disorders, cancer, and graft-versus-host disease.Type: GrantFiled: November 14, 2016Date of Patent: February 18, 2020Assignees: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, NEW YORK UNIVERSITYInventors: Dan Littman, Jun R. Huh, Ruili Huang, Wenwei Huang, Erika Elaine Englund
-
Patent number: 10555942Abstract: The present invention concerns the use of emetine compounds for the treatment or prevention of Flavivirus infections, such as Zika virus infections. Aspects of the invention include methods for treating or preventing Flavivirus virus infection, such as Zika virus infection, by administering an emetine compound such as emetine or cephaeline, or a combination of two or more emetine compounds, to a subject in need thereof; methods for inhibiting Flavivirus infections such as Zika virus infections in a cell in vitro or in vivo; pharmaceutical compositions; packaged dosage formulations; and kits for treating or preventing Flavivirus infections, such Zika virus infections.Type: GrantFiled: October 10, 2018Date of Patent: February 11, 2020Assignees: Florida State University Research Foundation, Inc., The Johns Hopkins University, The United States of America, as Represented by the Secretary, Department of Health and Human ServicesInventors: Hengli Tang, Emily M. Lee, Anil Mathew Tharappel, Hongjun Song, Guo-Li Ming, Wei Zheng, Miao Xu, Shu Yang, Ruili Huang, Wenwei Huang, Khalida Shamim, Hao Li
-
Publication number: 20190315740Abstract: Disclosed are compounds of formula (I) and formula (II): (I) (II) wherein R1, R2, A, and B are as defined herein. Also disclosed is a method of blocking transmission of a Plasmodium parasite and a method of treating or preventing malaria comprising administering to an animal an effective amount of a first compound of formula (I) or (II) either alone or in combination with a second compound selected from elesclomol, NSC174938, NVP-AUY922, Maduramicin, Narasin, Alvespimycin, Omacetaxine, Thiram, Zinc pyrithione, Phanquinone, Bortezomib, Salinomycin sodium, Monensin sodium, Dipyrithione, Dicyclopentamethylene-thiuram disulfide, YM155, Withaferin A, Adriamycin, Romidepsin, AZD-1152-HQPA, CAY10581, Plicamycin, CUDC-101, Auranofin, Trametinib, GSK-458, Afatinib, and Panobinostat.Type: ApplicationFiled: October 13, 2017Publication date: October 17, 2019Applicants: The United States of America,as represented by the Secretary,Department of Health and Human Services, Loyola University of ChicagoInventors: Wenwei Huang, Hao Li, Wei Sun, Xiuli Huang, Paresma R. Patel, Hangmao Sun, Wei Zheng, Xiao Lu, Philip E. Sanderson, Myunghoon Kim, Meghan J. Orr, Gregory J. Tawa, Kim C. Williamson
-
Publication number: 20190105318Abstract: The present invention concerns the use of emetine compounds for the treatment or prevention of Flavivirus infections, such as Zika virus infections. Aspects of the invention include methods for treating or preventing Flavivirus virus infection, such as Zika virus infection, by administering an emetine compound such as emetine or cephaeline, or a combination of two or more emetine compounds, to a subject in need thereof; methods for inhibiting Flavivirus infections such as Zika virus infections in a cell in vitro or in vivo; pharmaceutical compositions; packaged dosage formulations; and kits for treating or preventing Flavivirus infections, such Zika virus infections.Type: ApplicationFiled: October 10, 2018Publication date: April 11, 2019Inventors: Hengli TANG, Emily M. LEE, Anil Mathew THARAPPEL, Hongjun SONG, Guo-Li MING, Wei ZHENG, Miao XU, Shu YANG, Ruili HUANG, Wenwei HUANG, Khalida SHAMIM, Hao LI
-
Publication number: 20180015153Abstract: The present invention concerns the use of compounds for the treatment or prevention of Flavivirus infections, such as Zika virus infections. Aspects of the invention include methods for treating or preventing Flavivirus virus infection, such as Zika virus infection, by administering a compound or class of compound disclosed herein, such as a niclosamide compound, an emricasan compound, a cyclin-dependent kinase inhibitor, a proteasome inhibitor, or a combination of two or more of the foregoing, to a subject in need thereof; methods for inhibiting Flavivirus infections such as Zika virus infections in a cell in vitro or in vivo; pharmaceutical compositions; packaged dosage formulations; and kits for treating or preventing Flavivirus infections, such Zika virus infections.Type: ApplicationFiled: July 14, 2017Publication date: January 18, 2018Inventors: HENGLI TANG, EMILY M. LEE, YICHEN CHENG, YI ZHOU, WEI ZHENG, RUILI HUANG, MIAO XU, WENWEI HUANG, MENGHANG XIA, HONGJUN SONG, GUO-LI MING, ZHEXING WEN
-
Patent number: 9765063Abstract: Amido compounds are disclosed that have a formula represented by the following: and wherein Cy1, Cy2, n1, n2, R1a, R1b, R2, R3, R4, R5, and R6 are as described herein. The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, inflammatory conditions, autoimmune disorders, cancer, and graft-versus-host disease.Type: GrantFiled: September 10, 2012Date of Patent: September 19, 2017Assignees: New York University, The United States of America, as Represented by the Secretary, Department of Health and Human ServicesInventors: Dan Littman, Jun R. Huh, Ruili Huang, Wenwei Huang, Erika E. Englund
-
Publication number: 20170065606Abstract: Amido compounds are disclosed that have a formula represented by the following: and wherein n1, n2, R1a, R1b, R2, R3, R4, R5, and R6 are as described herein. The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, inflammatory conditions, autoimmune disorders, cancer, and graft-versus-host disease.Type: ApplicationFiled: November 14, 2016Publication date: March 9, 2017Inventors: Dan LITTMAN, Jun R. HUH, Ruili HUANG, Wenwei HUANG, Erika Elaine ENGLUND
-
Patent number: 9532989Abstract: The present invention relates to compounds of Formula P-I where the variables (e.g. R1, Y, A, R1, Ra, Ra?, Rb, Rb?, Rc, Rc?, Rd, Rd?, Re, or Re?) and compositions useful for inhibiting and/or reducing platelet deposition, adhesion and/or aggregation. The present invention further relates to methods for the treatment or prophylaxis of thrombotic disorders, including stroke, myocardial infarction, unstable angina, peripheral vascular disease, abrupt closure following angioplasty or stent placement and thrombosis as a result of vascular surgery.Type: GrantFiled: June 4, 2015Date of Patent: January 3, 2017Assignees: THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI, THE ROCKEFELLER UNIVERSITYInventors: Barry S. Coller, Craig Thomas, Marta Filizola, Joshua McCoy, Wenwei Huang, Min Shen
-
Patent number: 9492439Abstract: Amido compounds are disclosed that have a formula represented by the following: and wherein n1, n2, R1a, R1b, R2, R3, R4, R5, and R6 are as described herein. The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, inflammatory conditions, autoimmune disorders, cancer, and graft-versus-host disease.Type: GrantFiled: March 11, 2011Date of Patent: November 15, 2016Assignees: New York University, The United States of America, as Represented by the Secretary, Department of Health and Human ServicesInventors: Dan Littman, Jun R. Huh, Wenwei Huang, Ruili Huang, Erika Elaine Englund
-
Patent number: 9458141Abstract: Disclosed are oxo-hydroquinazolines that are useful as selective TSHR agonists. The compounds may be used for detecting or treating thyroid cancer, or treating a bone degenerative disorder.Type: GrantFiled: September 29, 2015Date of Patent: October 4, 2016Assignees: The United States of America, as Represented by the Secretary, Department of Health and Human Services, Forschungsverbund Berlin, E.V.Inventors: Marvin C. Gershengorn, Susanne Neumann, Bruce M. Raaka, Craig J. Thomas, James Inglese, Noel T. Southall, Steven Titus, Wei Zheng, Wenwei Huang, Gerd Krause, Gunnar Kleinau
-
Publication number: 20160264570Abstract: The invention provides a method of blocking transmission of a Plasmodium parasite and a method of treating or preventing malaria comprising administering to an animal an effective amount of a first compound of formula I: wherein A, B, R1, R2, R10, and R11 are described herein, either alone or in combination with a second compound selected from elesclomol, NSC 174938, NVP-AUY922, Maduramicin, Narasin, Alvespimycin, Omacetaxine, Thiram, Zinc pyrithione, Phanquinone, Bortezomib, Salinomycin sodium, Monensin sodium, Dipyrithione, Dicyclopentamethylene-thiuram disulfide, YM155, Withaferin A, Adriamycin, Romidepsin, AZD-1 152-HQPA, CAY10581, Plicamycin, CUDC-101, Auranofin, Trametinib, GSK-458, Afatinib, and Panobinostat.Type: ApplicationFiled: November 14, 2014Publication date: September 15, 2016Inventors: John C. McKew, Wei Zheng, Kim C. Williamson, Wenwei Huang, Wei Sun, Takeshi Tanaka, Seameen Jean Dehdashti, Noel Terrence Southall, Crystal Tobin Magle, Xiuli Huang, Paresma Rasiklal Patel, Myunghoon Kim
-
Patent number: 9303044Abstract: The present invention relates to compounds and compositions of Formula P useful for inhibiting and/or reducing platelet deposition, adhesion and/or aggregation. The definitions of variables A, B, R2, R3, R4, Ra, Ra?, Rb, Rb?, Rc, Rd, Rd?, Re, and Re? are provided in the disclosure. The present invention further relates to methods for the treatment or prophylaxis of thrombotic disorders, including stroke, myocardial infarction, unstable angina, peripheral vascular disease, abrupt closure following angioplasty or stent placement and thrombosis as a result of vascular surgery.Type: GrantFiled: January 16, 2013Date of Patent: April 5, 2016Assignees: THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, THE ROCKEFELLER UNIVERSITY, ICAHN SCHOOL OF MEDICINE AT MOUNT SINAIInventors: Barry S. Coller, Craig Thomas, Marta Filizola, Joshua McCoy, Wenwei Huang, Min Shen, Jian-Kang Jiang
-
Patent number: 9296729Abstract: Disclosed are oxo-hydroquinazolines that are useful as selective TSHR agonists. The compounds may be used for detecting or treating thyroid cancer, or treating a bone degenerative disorder.Type: GrantFiled: April 2, 2014Date of Patent: March 29, 2016Assignees: The United States of America as Represented by the Secretary of the Department of Health and Human Services, Forschungsverbund Berlin E.V.Inventors: Marvin C. Gershengorn, Susanne Neumann, Bruce M. Raaka, Craig J. Thomas, James Inglese, Noel T. Southall, Steven Titus, Wenwei Huang, Gerd Krause, Gunnar Kleinau, Wei Zheng
-
Publication number: 20160024023Abstract: Disclosed are oxo-hydroquinazolines that are useful as selective TSHR agonists. The compounds may be used for detecting or treating thyroid cancer, or treating a bone degenerative disorder.Type: ApplicationFiled: September 29, 2015Publication date: January 28, 2016Applicants: Health and Human Services, Forschungsverbund Berlin E.V.Inventors: Marvin C. Gershengorn, Susanne Neumann, Bruce M. Raaka, Craig J. Thomas, James Inglese, Noel T. Southall, Steven Titus, Wei Zheng, Wenwei Huang, Gerd Krause, Gunnar Kleinau